Haemonetics (NYSE:HAE) Price Target Raised to $96.00

Haemonetics (NYSE:HAE) had its price target increased by BTIG Research from $84.00 to $96.00 in a research note published on Thursday morning, MarketBeat reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

Other equities research analysts have also issued reports about the company. Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. Citigroup restated a “buy” rating on shares of Haemonetics in a research report on Wednesday, July 29th. Mizuho boosted their price target on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. lowered their price target on Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Finally, Barrington Research dropped their price objective on Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.89.

Haemonetics Price Performance

NYSE:HAE opened at $87.50 on Thursday. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.87 and a current ratio of 3.08. The company has a 50-day moving average of $76.98 and a 200-day moving average of $66.52. Haemonetics has a 52 week low of $47.31 and a 52 week high of $88.58. The company has a market capitalization of $3.98 billion, a price-to-earnings ratio of 42.89, a PEG ratio of 1.77 and a beta of 0.52.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The business had revenue of $339.38 million for the quarter, compared to analysts’ expectations of $327.86 million. During the same quarter in the previous year, the firm posted $1.10 earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, equities research analysts anticipate that Haemonetics will post 5.21 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Several hedge funds have recently modified their holdings of HAE. Kemnay Advisory Services Inc. acquired a new position in shares of Haemonetics in the 4th quarter worth approximately $26,000. Leonteq Securities AG bought a new stake in shares of Haemonetics during the fourth quarter worth $30,000. EverSource Wealth Advisors LLC increased its stake in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Haemonetics in the fourth quarter valued at $34,000. Finally, Kelleher Financial Advisors bought a new position in shares of Haemonetics in the second quarter valued at about $38,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Key Headlines Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, exceeding the $1.07–$1.08 consensus range. Revenue rose 5.5% year over year to $339.4 million, also comfortably ahead of expectations near $327.9 million. The earnings and sales beats indicate continued operating momentum. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook and now expects reported revenue growth of approximately 5% to 8%. The improved forecast, following a strong first quarter, supports the view that demand and execution are better than previously anticipated. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its Haemonetics price target from $84 to $96 and maintained a “buy” rating, implying additional upside based on the company’s earnings performance and outlook. BTIG Raises Haemonetics Price Target
• Neutral Sentiment: Citigroup lifted its price target from $79 to $92, while retaining a “neutral” rating. The higher target reflects improved estimates but suggests limited conviction at the current valuation. Citigroup Analyst Update
• Neutral Sentiment: JPMorgan raised its target from $62 to $86 but maintained a “neutral” rating. The revised target remains slightly below the recent trading level, signaling that valuation may constrain further gains despite the improved outlook. JPMorgan Analyst Update

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.